Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antibody-based therapeutic strategies for malignant lymphomas

Antibody-based therapeutic strategies for malignant lymphomas Antibody-based therapies have dramatically changed the course of disease in malignant lymphoma. Induction therapy has progressed from monotherapy to immunochemotherapy and radioimmunotherapy. In addition, maintenance treatment is now part of the standard treatment. A large number of antibodies against various targets is in routine use or currently tested in clinical trials. Second and third generation antibodies have improved cell killing properties and promise higher effectiveness. These new developments as well as upcoming strategies against novel targets in lymphoma are reviewed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Antibody-based therapeutic strategies for malignant lymphomas

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/antibody-based-therapeutic-strategies-for-malignant-lymphomas-jwgMCKsOAJ
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0102-1
Publisher site
See Article on Publisher Site

Abstract

Antibody-based therapies have dramatically changed the course of disease in malignant lymphoma. Induction therapy has progressed from monotherapy to immunochemotherapy and radioimmunotherapy. In addition, maintenance treatment is now part of the standard treatment. A large number of antibodies against various targets is in routine use or currently tested in clinical trials. Second and third generation antibodies have improved cell killing properties and promise higher effectiveness. These new developments as well as upcoming strategies against novel targets in lymphoma are reviewed.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Schulz, H; Bohlius, JF; Trelle, S
  • Rituximab maintenance therapy: a step forward in follicular lymphoma
    Van Oers, MH
  • Patient benefits of maintenance immunotherapy
    Ghielmini, M
  • Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
    Morschhauser, F; Radford, J; Van Hoof, A